Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What CAGR And Valuation Are Anticipated For The Rare Disease Diagnostics Market?
In recent times, there has been a substantial growth in the market size for rare disease diagnostics. The market is anticipated to expand from $35.23 billion in 2024 to $38.14 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.3%. Factors contributing to this growth during the historic period include the increased need for cloud-based diagnostics, a heightened focus on enhancing efficiency, a rise in neurological disease instances, a surge in immunological disorders, and a boost to healthcare expenditure.
In the next several years, the market for rare disease diagnostics is projected to exhibit considerable growth, reaching a valuation of $56.08 billion in 2029 with a compound annual growth rate (CAGR) of 10.1%. Factors contributing to this growth during the forecast period include the rising incidence of rare diseases, enhanced government initiatives, an increase in the number of hospitals and diagnostic laboratories, the growth of hematology diseases, and improvements in healthcare infrastructure. The time frame for the forecast also entails significant developments in genetic testing technologies, the inception of whole-genome sequencing and next-generation sequencing (NGS), comprehensive financial investments, and strategic partnerships for research endeavors.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12651&type=smp
What Core Drivers Are Expected To Influence The Rare Disease Diagnostics Market?
The rise in the occurrence of rare diseases is predicted to stimulate the expansion of the rare disease diagnostics market in future. A rare disease is a health problem with a low prevalence rate, affecting a minuscule number of people compared to other common diseases within the population. Diagnostics for rare diseases play a crucial role in disease management, identifying potential therapies, and avoiding treatments that could lead to severe side effects, thereby aiding in effective therapy. To illustrate, Health Match, an Australian digital health firm, reported in November 2022 that there are about 150 rare kidney conditions that occur quite frequently globally, with 60–80 cases per 100,000 individuals in the US and Europe. Hence, the escalating rate of rare diseases is bolstering the development of the rare disease diagnostics market.
What Are The Main Segment Classifications In The Rare Disease Diagnostics Market?
The rare disease diagnosticsmarket covered in this report is segmented –
1) By Test Type: Genetic Test; General Lab Test; Imaging Test
2) By Technology: Capillary Sequencing; Whole Genome Sequencing; Whole Exome Sequencing; Microarrays
3) By Sample Type: Deoxyribonucleic Acid (DNA) Sample; Buccal Swab Sample; Blood; Saliva
4) By Disease Type: Gastroenterology Disease; Endocrine And Metabolism Disorders Disease; Hematology And Oncology Disease; Dermatology Disease; Cardiovascular Disorders; Neurology Disease
5) By End User: Hospital Laboratories; Diagnostics Laboratories; Genetic Testing Laboratories; Cancer Research Laboratories
Subsegments:
1) By Genetic Test: Whole Genome Sequencing; Targeted Gene Panels; Exome Sequencing; Carrier Testing
2) By General Lab Test: Blood Tests; Biochemical Assays; Urine Tests; Cytogenetic Tests
3) By Imaging Test: MRI (Magnetic Resonance Imaging); CT (Computed Tomography) Scans; Ultrasound; X-Rays
How Are Industry Trends Steering The Expansion Of The Rare Disease Diagnostics Market?
The rare disease diagnostics market is witnessing a significant trend in the form of technological advancements. To maintain their market position, prominent firms in the market are embracing these cutting-edge technologies. For example, in April 2023, Centogene GmbH, a firm specializing in rare diseases based in Germany, introduced a new solution called CentoGenome, which leverages whole genome sequencing for diagnosing rare and neurodegenerative diseases. The new CentoGenome employs an advanced next-generation sequencing (NGS)-based assay, offering whole genome sequencing (WGS) tests covering almost all disease-causing variants within a single assay. Besides, it also provides unmatched sensitivity for detecting Copy Number Variations (CNVs) associated to Spinal Muscular Atrophy (SMA), alongside complex disease-causing variations linked to Gaucher Disease (GD) and GBA1-related Parkinson’s Disease (PD) susceptibility. By employing PCR (polymerase chain reaction)-free technology in tricky genomic areas, CentoGenome can significantly reduce bias and deliver high-grade sequencing data, enabling a deeper comprehension of coding, regulatory, and intronic areas.
Which Companies Are Contributing Significantly To The Rare Disease Diagnostics Market Growth?
Major companies operating in the rare disease diagnostics market include Thermo Fisher Scientific Inc., Roche Diagnostics, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Astellas Pharma Inc., Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Sanofi Genzyme, Illumina Inc., Bio-Rad Laboratories Inc., Qiagen NV, BioMarin Pharmaceutical Inc., OPKO Health Inc., Sarepta Therapeutics Inc., Natera Inc., Invitae Corporation, Ultragenyx Pharmaceutical Inc., Travere Therapeutics Inc., BGI Genomics Co. Ltd., 23andMe Holding Co., Ambry Genetics Corporation, Centogene N.V., GENEWIZ Inc., Blueprint Genetics Inc., Oxford Gene Technology Limited, Strand Life Sciences Pvt. Ltd., Agios Pharmaceuticals Inc., Orphazyme A/S, RareCyte Inc.
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report
Which Region Holds The Greatest Opportunity For Rare Disease Diagnostics Market Expansion?
North America was the largest region in the rare disease diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=12651&type=smp
Browse Through More Reports Similar to the Global Rare Disease Diagnostics Market 2025, By The Business Research Company
Rare Diseases Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report
Rare Sugar Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/rare-sugar-global-market-report
Rare Kidney Diseases Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model